Click on image to view larger version.

Figure 2 Anti-Xa activity in excluded and non-excluded patients measured after the third injection or just before the coronary angiogram. The distribution of anti-Xa activity matches perfectly in both groups. Nearly all patients (94.4%) had an anti-Xa level above the lower limit of the therapeutic range (0.5 IU/ml), most of them being close to the upper limit (1 IU/ml).